title: Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Miyasaka
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Tatsuki
authors.forename: Toshiro
authors.initials: T
authors.lastname: Yano
authors.forename: Toru
authors.initials: T
authors.lastname: Yoshinari
authors.forename: Tohru
authors.initials: T
authors.lastname: Abe
authors.forename: Takao
authors.initials: T
authors.lastname: Koike
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D015850:Interleukin-6 / Q000097:blood; D008727:Methotrexate / Q000008:administration & dosage; D012074:Remission Induction; D000093242:Interleukin-6 Inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab; D015850:Interleukin-6; D008727:Methotrexate; D000093242:Interleukin-6 Inhibitors; C508600:IL6 protein, human